news
Five HERV expression signatures linked to psychiatric disorders
This is the first study to demonstrate that a specific set of HERVs expressed in the human brain contribute to disorders like schizophrenia.
List view / Grid view
Schizophrenia
article
Documenting the mammalian brain using machine learning
Novel approaches to brain disorder diagnosis and treatment may be developed following a project to form a map of the mouse hippocampus.
news
Incorporating microglia into brain organoids
iPS-cell-derived microglia in brain organoids have enabled scientists to understand early brain development and microglia-associated disease.
news
Placenta’s role in genetic risk of schizophrenia
A recent study led by the Lieber Institute for Brain Development has revealed that over 100 genes associated with the risk of schizophrenia appear to contribute to the development of the illness primarily through their influence on the placenta.
news
Scientists discover multiple pathways of the 5HT2a receptor activated by psychedelics
The new LSD-like compounds activated the 5HT2a receptor, a receptor stimulated by serotonin, without causing hallucinations.
news
Researchers use brain organoids to identify neural abnormalities and test gene therapy tools
Scientists used human brain organoids to reveal how a genetic mutation associated with a profound form of autism disrupts neural development, and gene therapy tools to recover the gene’s function effectively rescued neural structure and function.
news
Scientists explore CA2 neuron mitochondria for memory loss targets
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
news
Thalamus revealed as key area to target for certain brain disorders
Research shows that cells gather more data inside the thalamus than once believed, potentially changing medicines for brain disorders.
podcasts
Episode 1 – Dr Sri Gopal, Janssen Pharmaceuticals
Listen along to learn more about drug development for schizophrenia from Dr Sri Gopal, Head of Psychiatry R&D for Janssen!
news
Synapse protecting protein could be a target for Alzheimer’s therapies
Researchers suggest the SRPX2 protein, which inhibits complement system-dependent synapse removal could be a target for novel Alzheimer’s and schizophrenia therapies.
news
Ion channel ball-and-chain mechanism imaged after decades of attempts
Scientists have imaged the ball-and-chain mechanism using cryogenic electron microscopy and hope their work could be applied in the design of novel therapeutics.
article
Safer and more affordable medicine for all? How pharmacogenomics may level the playing field
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
news
Key modifier identified in genetic deletion related to autism
A key modifier has been identified by researchers in a large fruit fly genetic deletion related to neurodevelopmental disorders such as schizophrenia and autism.
news
Interaction site for serotonin type 3A and RIC-3 chaperone identified
To address the receptor dysfunction associated with several neurological diseases, scientists have provided novel insights into a protein-protein interaction that could lead to more effective treatments.
news
Lower levels of SV2A protein identified as drug target for schizophrenia
Using brain scans, a study has shown that schizophrenia patients have lower levels of the protein SV2A in their brains which presents a drug target.